327 related articles for article (PubMed ID: 3049804)
41. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
42. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
43. Critical roles of memory T cells and antidonor immunoglobulin in rejection of allogeneic bone marrow cells in sensitized recipient mice.
Nagata S; Okano S; Yonemitsu Y; Nakagawa K; Tomita Y; Yoshikai Y; Shimada M; Maehara Y; Sueishi K
Transplantation; 2006 Sep; 82(5):689-98. PubMed ID: 16969294
[TBL] [Abstract][Full Text] [Related]
44. Bone marrow transplantation across major histocompatibility barriers in rabbits. I. A positive role for graft-versus-host reactivity in engraftment.
Adler LT; Annaratone LJ; LeBeau MM
Bone Marrow Transplant; 1990 Jan; 5(1):51-6. PubMed ID: 2297590
[TBL] [Abstract][Full Text] [Related]
45. Selective elimination of non-lpr lymphoid cells in mice undergoing lpr-mediated graft-vs-host disease.
Perkins DL; Michaelson J; Glaser RM; Marshak-Rothstein A
J Immunol; 1987 Sep; 139(5):1406-13. PubMed ID: 2887617
[TBL] [Abstract][Full Text] [Related]
46. Recipient type-specific engineered regulatory T cells prevent graft-vs-host disease after allogeneic bone marrow transplantation in mice.
Chen C; Cao J; Zeng L; Li Y; Wang D; Xu K
Transplant Proc; 2011 Jun; 43(5):2041-8. PubMed ID: 21693322
[TBL] [Abstract][Full Text] [Related]
47. Ex vivo treatment of murine splenocyte-supplemented bone marrow inocula with mafosfamide prior to allogeneic transplantation in an attempt to prevent lethal graft-versus-host disease without compromising engraftment.
Kohn FR; Sladek NE
Immunopharmacol Immunotoxicol; 1988; 10(3):387-98. PubMed ID: 3058776
[TBL] [Abstract][Full Text] [Related]
48. Influence of the additional injection of host-type bone marrow on the immune tolerance of minor antigen-mismatched chimeras: possible involvement of double-negative (natural killer) T cells.
Sefrioui H; Billiau AD; Overbergh L; Rutgeerts O; Waer M
Transplantation; 1999 Nov; 68(10):1560-7. PubMed ID: 10589955
[TBL] [Abstract][Full Text] [Related]
49. Allogeneic versus semiallogeneic F1 bone marrow transplantation into sublethally irradiated MHC-disparate hosts. Effects on mixed lymphoid chimerism, skin graft tolerance, host survival, and alloreactivity.
Pierce GE
Transplantation; 1990 Jan; 49(1):138-44. PubMed ID: 2137269
[TBL] [Abstract][Full Text] [Related]
50. Multiple mixed chimeras: reconstitution of lethally irradiated mice with syngeneic plus allogeneic bone marrow from multiple strains.
Chester CH; Sykes M; Sachs DH
Res Immunol; 1989; 140(5-6):503-16. PubMed ID: 2675227
[TBL] [Abstract][Full Text] [Related]
51. Experimental and clinical gnotobiotics: influence of the microflora on graft-versus-host disease after allogeneic bone marrow transplantation.
Heidt PJ; Vossen JM
J Med; 1992; 23(3-4):161-73. PubMed ID: 1479298
[TBL] [Abstract][Full Text] [Related]
52. Suppressor T cells in allogeneic bone marrow chimeras.
Leshem B; Lebendiker Z; Weiss L; Slavin S; Kedar E
Bone Marrow Transplant; 1987 Aug; 2(2):123-32. PubMed ID: 2901877
[TBL] [Abstract][Full Text] [Related]
53. Bone marrow transplantation from mutant lpr/lpr mice. Functional abnormalities rather than alloantigenic differences appear to determine the development of a graft-vs.-host-like syndrome.
Allen RD; Marshall JD; Roths JB; Sidman CL
Eur J Immunol; 1990 Sep; 20(9):2057-66. PubMed ID: 2209703
[TBL] [Abstract][Full Text] [Related]
54. The mechanism of graft-host-tolerance in murine radiation chimeras transplanted across minor histocompatibility barriers.
Perreault C; Bélanger R; Gyger M; Allard A; Brochu S
Bone Marrow Transplant; 1989 Jan; 4(1):83-7. PubMed ID: 2647191
[TBL] [Abstract][Full Text] [Related]
55. Immune competence of splenic lymphocytes following graft-vs-host disease in mouse allogeneic radiation chimeras.
Urso P; Gengozian N
J Immunol; 1977 Feb; 118(2):657-61. PubMed ID: 14214
[TBL] [Abstract][Full Text] [Related]
56. Prevention of graft-versus-host disease in allogeneic bone marrow transplantation by pretreatment with 2'-deoxycoformycin.
Epstein J; Bealmear PM; Kennedy DW; Herrmann MJ; Islam A; Wiedl SC
Exp Hematol; 1986 Oct; 14(9):845-9. PubMed ID: 2944759
[TBL] [Abstract][Full Text] [Related]
57. The effect of T cell depletion from spleen cell allografts on graft-versus-host disease and long-term immune reconstitution in H-2 haplotype-identical murine combinations.
Tokuda N; Mayumi H; Sakumoto M; Himeno K; Tomita Y; Nomoto K
Immunobiology; 1989 Oct; 179(4-5):328-41. PubMed ID: 2515151
[TBL] [Abstract][Full Text] [Related]
58. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease.
Johnson BD; Truitt RL
Blood; 1995 Jun; 85(11):3302-12. PubMed ID: 7756664
[TBL] [Abstract][Full Text] [Related]
59. Improved immune function with donor B-cell infusion after semi-allogeneic bone marrow transplantation in mice.
Samuel S; Azar Y; Corchia N; Or R
Arch Med Res; 2008 Jan; 39(1):61-8. PubMed ID: 18067997
[TBL] [Abstract][Full Text] [Related]
60. Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation.
Truitt RL; Atasoylu AA
Blood; 1991 Jun; 77(11):2515-23. PubMed ID: 2039833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
